港股異動 | 神威藥業(2877.HK)拉昇逾6% 中期淨利潤升21.6% 線上銷售大增280.4%
格隆匯8月31日丨神威藥業(02877.HK)午後拉昇逾6%,報8.2港元,總市值68億港元。神威藥業今日午間公佈中期業績,截至2021年6月30日止6個月,集團營業額為人民幣15.54億元,比去年同期上升30.6%;期內溢利為人民幣3.08億元,比去年同期上升21.6%。此外,集團互聯網數字營銷團隊2021年上半年完成了線上銷售約人民幣7900萬元,比去年同期增長280.4%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.